Patients with drug resistant forms of breast cancer and some forms of pancreatic cancer may have new hope, thanks to a new drug first developed at Griffith and now being trialled in the Czech Republic.
Clinical trials of the experimental drug MitoTam are beginning imminently in the Czech Republic with funding from a local venture capital firm Smart Brain.
Professor Jiri Neuzil from Griffith’s School of Medical Science is leading the clinical trials involving patients with the triple negative tumours which are known to be very hard to treat.
The drug has been modified from the commonly used breast cancer drug Tamoxifen to target the mitochondria of a patient’s cancer cells to make a more efficient compound that is able to kill resistant cancer cells.
Tamoxifen is ineffective in treating triple negative tumours or tumours with a high level of HER2, a protein found on the surface of cancer cells.
Could revolutionise treatment
“MitoTam could revolutionise
Skip to content
News and other stories about real people, places, and events in Mount Gravatt and nearby suburbs.